In patients with coronary artery disease (CAD), robust evidence demonstrated significant risk reductions for CV disorders (n = 3), MACEs (n = 3), revascularisation procedures, stroke incidence, and high-sensitivity C-reactive protein (hs-CRP) levels. This evidence concerns the gene CRP and Stroke.